The New Technology and Gene Therapy Workshop has been held every few years since 1996 and was most recently hosted by the National Bleeding Disorders Foundation (NBDF). Building upon this history, the WFH organized the 18th edition, continuing a long tradition of advancing care for people with hemophilia through cutting-edge research.
Day one of the workshop focused on immunological issues and toxicities associated with gene transfer; monoclonal and bispecific antibodies for hemophilia and other coagulation disorders; and non-viral gene therapy/gene editing.
Presentations on day two covered the need for improved FVIII transgenes or alternatives; other vector systems and innovative clinical trials; and the latest updates on AAV vectors. A patient panel discussed the state of the science.
The 18th New Technology and Gene Therapy Workshop provided a unique opportunity for participants to come together, emphasizing the community’s commitment to advancing new technologies and ensuring that innovative treatments can benefit all patients
The 18th WFH New Technology and Gene Therapy Workshop was supported by:
Visionary partners: CSL Behring and Spark Therapeutics
Leading partner: Pfizer
Collaborating partner: Biomarin
With additional thanks to: HC Bioscience, Hemab, Metagenomi, NBDF, STAR therapeutics